Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 15/20 | 0.60 |
| ▸ | HTR2A | P28223 | 7/20 | 0.60 |
| ▸ | HTR2C | P28335 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18690953 | 0.82 | HTR6 (0.67) | HTR6HTR2AHTR2CKMT2ALMNA | |
| SCHEMBL28433656 | 0.82 | HTR6 (0.56) | HTR6HTR2AHTR2CKMT2AMEN1 | |
| SCHEMBL18690960 | 0.81 | HTR6 (0.59) | HTR6HTR2AHTR2C | |
| SCHEMBL16079468 | 0.80 | HTR6 (0.60) | HTR6HTR2AHTR2CL3MBTL1 | |
| SCHEMBL3619076 | 0.78 | HTR6 (0.52) | HTR6KMT2AMEN1L3MBTL1LMNA | |
| SCHEMBL17422026 | 0.78 | HTR6 (0.69) | HTR6HTR2AHTR2CL3MBTL1LMNA | |
| SCHEMBL13378914 | 0.78 | HTR6 (0.51) | HTR6HTR2AHTR2CLMNA | |
| SCHEMBL18690957 | 0.77 | HTR6 (0.62) | HTR6HTR2AHTR2C | |
| SCHEMBL3623180 | 0.76 | KDM4E (0.56) | HTR6HTR2AKMT2AMEN1L3MBTL1 | |
| SCHEMBL23144691 | 0.75 | HTR2A (0.46) | HTR6HTR2AHTR2CKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11814373-B2 | Methods and compounds for restoring mutant p53 function | PMV PHARMACEUTICALS, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20230312539-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2023-10-05 | — | — | US | disclosed |
| EP-4034104-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION | PMV Pharmaceuticals, Inc. (US) | 2022-08-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230312539-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | TP53, TP53BP1, KRAS | HTR6 3745/4885HTR2A 4346/4885HTR2C 4337/4885 |
| US-11814373-B2 | Methods and compounds for restoring mutant p53 function | TP53, TP53BP1, KRAS | HTR6 3745/4885HTR2A 4346/4885HTR2C 4337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.